| Tecentriq (atezolizumab) / Roche |
QUILT-3.055, NCT03228667: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors |
|
|
| Active, not recruiting | 2b | 147 | US | N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK | ImmunityBio, Inc. | Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer | 05/24 | 12/24 | | |
|
NCT04471415: Study to Investigate DRP-104 in Adults With Advanced Solid Tumors |
|
|
| Terminated | 2a | 61 | Europe, US, RoW | DRP-104, atezolizumab | Dracen Pharmaceuticals, Inc. | Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic | 03/23 | 03/23 | | |
jRCT1041200068: Phase II study of atezolizumab + bevacizumab combination therapy in patients with advanced hepatocellular carcinoma with a history of drug therapy |
|
|
| Active, not recruiting | 2 | 28 | Japan | Tecentriq (atezolizumab) - Roche, Avastin (bevacizumab) - Roche | Kanazawa University Hospital | Hepatocellular carcinoma | | | | |
NEJ043, jRCTs031190066: A Phase 2 Study of atezolizumab + carboplatin + paclitaxel + bevacizumab for previously-treated patients with NSCLC harboring EGFR mutations. |
|
|
| Completed | 2 | 60 | Japan | Tecentriq (atezolizumab) - Roche, carboplatin - Generic mfg., paclitaxel - Generic mfg., Avastin (bevacizumab) - Roche | Niigata University Medical and Dental Hospital | Non-squamous non-small cell lung cancer | | | | |
| Active, not recruiting | 2 | 20 | Japan | Tecentriq (atezolizumab) - Roche | National Cancer Center Hospital, Chugai Pharmaceutical Co., Ltd. | Unresectable alveolar soft tissue sarcoma | | | | |
| Recruiting | 2 | 33 | Japan | cisplatin - Generic mfg., vinorelbine tartrate - Generic mfg., Tecentriq (atezolizumab) - Roche | Kitakyushu Municipal Medical Center, Chugai Pharmaceutical Co., Ltd. | Non-small cell lung cancer | | | | |
| Completed | 2 | 119 | Europe, Canada, US | Atezolizumab, MPDL3280A, Tecentriq | Hoffmann-La Roche | Bladder Cancer | 07/16 | 02/23 | | |
|
|
NCT02108652: A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) |
|
|
| Completed | 2 | 310 | Europe, Canada, US | Atezolizumab, MPDL3280A, Tecentriq | Hoffmann-La Roche | Bladder Cancer | 07/16 | 02/23 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2016-004744-11: PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study of Atezolizumab and chemoradiation (PERFECT) Haalbaarheidsonderzoek naar de behandeling van preoperatieve chemoradiotherapie en atezolizumab gevolgd door operatie bij patiënten met slokdarmkanker |
|
|
| Ongoing | 2 | 40 | Europe | Tecentriq, Concentrate and solvent for solution for infusion, tecentriq | Academic Medical Center, University of Amsterdam | oesophageal cancer slokdarmkanker, oesophageal cancer slokdarmkanker, Diseases [C] - Cancer [C04] | | | | |
2016-005019-42: A clinical trial aiming to assess the effect of an immunotherapy for the treatment of soft tissue sarcomas treated by radiotherapy. Essai clinique évaluant l'effet d'une immunothérapie chez des patients atteints de sarcomes des tissu mous traités par radiothérapie. |
|
|
| Ongoing | 2 | 69 | Europe | Atezolizumab, Solution for injection, TECENTRIQ | Centre Léon Bérard, Centre Léon Bérard, F-Hoffman La ROCHE | localised and operable soft tissue sarcomas sarcomes des tissus mous opérables et localisés, soft tissue cancers that are localised and operable cancer des tissus mous localisé et opérables, Diseases [C] - Cancer [C04] | | | | |
2017-003353-41: Mesothelioma Stratified Therapy (MiST) - Including the following treatment arms: MiST 1 rucaparibMiST 2 abemaciclibMiST 3 pembrolizumab in combination with bemcentinibMiST 4 atezolizumab in combination with bevacizumabMiST 5 dostarlimab in combination with niraparib |
|
|
| Not yet recruiting | 2 | 120 | Europe | rucaparib, abemaciclib, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), Pembrolizumab, bemcentinib, KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib, Dostarlimab, CO-338, LY2835219, R05541267/F03, RO4876646/F01, RO4876646/F02, MK-3475, BGB324, Tablet, Capsule, hard, Concentrate for solution for infusion, Solution for infusion, Capsule, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib | University of Leicester, The British Lung Foundation, Clovis Pharmaceuticals Inc., Eli Lilly & Company, Roche Pharma AG, Merck Sharp & Dohme Limited, BerGenBio ASA, GlaxoSmithKline Research & Development Limited | Malignant Mesothelioma (MM) - pleural and peritoneal, Mesothelioma is a universally lethal cancer caused by Asbestos. There has only been one licenced therapy since 2003. Accordingly there is a pressing need for effective therapy in the relapsed setting, Diseases [C] - Cancer [C04] | | | | |
NCT03233698: Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery |
|
|
| Recruiting | 2 | 26 | US | Atezolizumab, Laboratory Biomarker Analysis, Pharmacological Study | National Cancer Institute (NCI) | Metastatic Alveolar Soft Part Sarcoma | 12/18 | 12/18 | | |
2018-002607-34: Atezolizumab in Advanced Non-small cell lung cancer with rare histologies Atezolizumab nel carcinoma polmonare non a piccole cellule avanzato con istologie rare |
|
|
| Ongoing | 2 | 43 | Europe | TECENTRIQ, [R00554-1267/F03-01], Concentrate for solution for infusion, TECENTRIQ - 1200 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO | GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC), Roche Spa | Advanced Non-small cell lung cancer (NSCLC) with rare histological subtypes Carcinoma polmonare non a piccole cellule avanzato (NSCLC) pretratto, con sottotipi istologici rari, Advanced Non-small cell lung cancer with rare histologies Carcinoma polmonare non a piccole cellule con sottotipi istologici rari, Diseases [C] - Cancer [C04] | | | | |
NCT03073525: A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers |
|
|
| Completed | 2 | 25 | US | Vigil, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy, FANG vaccine, Atezolizumab, TECENTRIQ™, MPDL3280A | Gradalis, Inc., Roche-Genentech | Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer | 05/19 | 05/22 | | |
2019-000727-41: A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies Étude multicentrique de phase II, ouverte, non randomisée, de phase II, évaluant le Platine-Pemetrexed-Atezolizumab (Bevacizumab) chez des patients atteints d'un cancer du poumon non à petites cellules non épidermoïde de stade IIIB/IV avec mutation EGFR, réarrangement ALK ou fusion ROS1, qui évolue après des traitements ciblés |
|
|
| Ongoing | 2 | 149 | Europe | Bevacizumab, Atezolizumab, L01XC07, RO5541267, Concentrate for solution for infusion, AVASTIN, Tecentriq | Centre François Baclesse, Centre François Baclesse | Patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after targeted therapies Patients atteints d'un cancer du poumon non épidermoïde non à petites cellules de stade IIIB/IV avec mutations EGFR, réarrangement ALK ou fusion ROS1 progressant après des traitements ciblés, Patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after targeted therapies Patients atteints d'un cancer du poumon non épidermoïde non à petites cellules de stade IIIB/IV avec mutations EGFR, réarrangement ALK ou fusion ROS1 progressant après des traitements ciblés, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 135 | Europe, US, RoW | Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Placebo | Genentech, Inc. | Non-small Cell Lung Cancer | 06/19 | 03/25 | | |
|
|
|
|
|
NCT03133390: Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients |
|
|
| Active, not recruiting | 2 | 2 | US | Atezolizumab 1200 mg, Tecentriq, Bevacizumab 15 mg/kg IV, Avastin | New York University School of Medicine | Urothelial Carcinoma | 07/19 | 01/20 | | |
2018-004348-47: EFFICACY OF ATEZOLIZUMAB COMBINED WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER EFICACIA DEL ATEZOLIZUMAB EN COMBINACIÓN CON RADIOTERAPIA EN PACIENTES CON CÁNCER DE VEJIGA MÚSCULO-INVASIVO |
|
|
| Not yet recruiting | 2 | 39 | Europe | Concentrate for solution for infusion, Tecentriq | Grupo Español de Oncología Genitourinaria (SOGUG), Roche | MUSCLE-INVASIVE BLADDER CANCER CÁNCER DE VEJIGA MÚSCULO-INVASIVO, MUSCLE-INVASIVE BLADDER CANCER CÁNCER DE VEJIGA MÚSCULO-INVASIVO, Diseases [C] - Cancer [C04] | | | | |
2018-002463-25: Neoadjuvant treatment in rectal cancer with radiotherapy followed by atezolizumab and bevacizumab (TARZAN) |
|
|
| Not yet recruiting | 2 | 38 | Europe | Tecentriq, Avastin, RO5541267/F05, RO4876646, Concentrate for solution for infusion, Avastin | Antoni van Leeuwenhoek, F. Hofman-la Roche | adenocarcinoma of the rectum, rectal cancer, Diseases [C] - Cancer [C04] | | | | |
2017-004239-35: Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas ETUDE DE PHASE II, RANDOMISEE EVALUANT L’IMMUNOTHERAPIE APRES HAUTE DOSE D’IRRADIATION (SBRT) VERSUS SBRT SEULE CHEZ LES PATIENTS PORTEURS DE SARCOMES OLIGOMETASTATIQUES |
|
|
| Not yet recruiting | 2 | 103 | Europe | atezolizumab, RO5541267, Concentrate for solution for infusion, Tecentriq | Centre Antoine Lacassagne, Institut National du Cancer, Roche SAS | Soft tissue sarcoma Sarcomes des tissus mous, Soft tissue sarcoma Sarcomes des tissus mous, Diseases [C] - Cancer [C04] | | | | |
| Ongoing | 2 | 52 | Europe | Atezolizumab, DKN-01, RO5541267, Concentrate for solution for infusion, Solution for injection/infusion, Atezolizumab | THE ROYAL MARSDEN NHS FOUNDATION | Patients with advanced mismatch repair proficient oesophagogastric cancer, Stomach cancer, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT02724878: Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 65 | US | Bevacizumab, Avastin, Atezolizumab, RG-7446 | Dana-Farber Cancer Institute, Genentech, Inc. | Advanced Non-Clear Cell Kidney Cancer | 11/19 | 10/24 | | |
NCT03483012: Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis |
|
|
| Active, not recruiting | 2 | 6 | US | Atezolizumab, Tecentriq, Stereotactic radiosurgery (SRS) | Dana-Farber Cancer Institute, Genentech, Inc. | Breast Cancer | 11/19 | 09/25 | | |
2018-004623-36: MEGALiT - a study in which the effect of established cancer drugs is investigated on new cancers that have a specific molecular signature MEGALiT - en studie där effekten av etablerade cancerläkemedel undersöks på nya cancersjukdomar som har en specifik molekylär signatur |
|
|
| Not yet recruiting | 2 | 154 | Europe | Tecentriq, Cotellic, Zejula, Everolimus, RO5514041/F04, Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Tecentriq, Cotellic, Zejula | Uppsala University Hospital, Roche AB | In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, Diseases [C] - Cancer [C04] | | | | |
2019-001707-21: Single-Arm Phase II-Study in Patients with extensive stage small cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide Untersuchung einer Atezolizumab-Carboplatin-Etoposid-Behandlung in Patienten mit weit fortgeschrittenem kleinzelligen Lungenkarzinom mit eingeschränktem Gesundheitszustand |
|
|
| Not yet recruiting | 2 | 70 | Europe | Atezolizumab, Carboplatin, Etopsid, L01XC32, Concentrate for solution for infusion, Tecentriq (R) | AIO-Studien-gGmbH, F. Hoffmann-La Roche Ltd. | treatment-naive, extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status with or without asymptomatic brain metastases (stage IV, ECOG=2) nicht vorbehandelte, weit fortgeschrittene kleinzellige Lungenkarzinome mit eingeschränktem Gesundheitszustand (Stadium IV mit ECOG PS = 2) mit oder ohne asymptomatische Hirnmetastasen, extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status nicht vorbehandelte, weit fortgeschrittene kleinzellige Lungenkarzinome mit eingeschränktem Gesundheitszustand, Diseases [C] - Cancer [C04] | | | | |
2019-000881-39: A phase II study evaluating the interest to combine UCPVax a CD4 TH1-inducer cancer vaccine and atezolizumab for the treatment of HPV positive cancers Etude de phase II évaluant l’intérêt d’associer le vaccin UCPVax et l’Atezolizumab dans le traitement des cancers HPV positifs |
|
|
| Not yet recruiting | 2 | 47 | Europe | atezolizumab, UCPVax, R05541267, Concentrate for solution for infusion, Solution for injection, Tecentriq | CHU de Besançon, CHU de Besançon | cancers induits par HPV (Human PapillomaVirus) (cancers ORL, du col de l'utérus, de la vulve et du canal anal cancers induits par HPV (Human PapillomaVirus) (cancers ORL, du col de l'utérus, de la vulve et du canal anal), cancers induits par HPV (Human PapillomaVirus) (cancers ORL, du col de l'utérus, de la vulve et du canal anal) cancers induits par HPV (Human PapillomaVirus) (cancers ORL, du col de l'utérus, de la vulve et du canal anal), Body processes [G] - Immune system processes [G12] | | | | |
2018-003902-14: Treatment of non-operable esophagogastric carcinoma cancer patients or non-operable biliary cancer who progressed/spread/ got worse after first line treatment with a novel combination of DKN-01/Atezolizumab with or without Paclitaxel: a Phase II trial |
|
|
| Not yet recruiting | 2 | 123 | RoW | DKN-01, Atezolizumab, Paclitaxel, LY2812176, Lyophilisate for solution for infusion, Concentrate for concentrate for solution for infusion, Concentrate for solution for infusion, Tecentriq, Paclitaxel (Generic) | European Organisation for Research and Treatment of Cancer, European Organisation for the Research and Treatment of Cancer, Leap Therapeutics, Inc, F. Hoffmann-La Roche Ltd. | Non-operable biliary tract cancer (BTC) and non-operable esophagogastric cancer (EGC) adenocarcinoma., Biliary Tract Cancer Esophagogastric Cancer, Diseases [C] - Cancer [C04] | | | | |
2019-001388-55: A Phase II Trial of atezolizumab plus carboplatin plus paclitaxel as first-line therapy in metastatic Triple-negative PD-L1 positive breast cancer patients Sperimentazione clinica di fase 2 che coinvolge pazienti affetti da un sottotipo di carcinoma mammario metastatico definito come triplo negativo e PD-L1 positivo |
|
|
| Ongoing | 2 | 104 | Europe | Atezolizumab, [RO554-1267], Concentrate for solution for infusion | CONSORZIO ONCOTECH, Roche spa | Metastatic Triple-negative PD-L1 positive breast cancer Carcinoma mammario metastatico Triplo-negativo PD-L1 positivo, metastatic Triple-negative PD-L1 positive breast cancer carcinoma mammario metastatico PD-L1 positivo e particolarmente difficile da trattare, Diseases [C] - Cancer [C04] | | | | |
2019-002430-36: Atezolizumab/bevacizumab followed by on-demand TACE or initial synchronous treatment with TACE and atezolizumab/bevacizumab Untersuchung der Wirksamkeit von Atezolizumab plus Bevacizumab gefolgt von einer selektiven TACE bei Bedarf oder einer Initial synchronen Behandlung mit TACE und Atezolizumab/Bevacizumab bei nicht resektablem hepatozellulärem Karzinom |
|
|
| Not yet recruiting | 2 | 106 | Europe | Concentrate for solution for injection/infusion, Concentrate for solution for infusion, Avastin, Tecentriq | Klinikum der Ludwig-Maximilians-Universität München -, Roche Pharma AG | Unresectable hepatocellular carcinoma (HCC) Nicht-resezierbares Hepatozelluläres Karzinom, Unresectable hepatocellular carcinoma (HCC) Nicht-resezierbares Hepatozelluläres Karzinom, Diseases [C] - Cancer [C04] | | | | |
2019-004771-40: ProTargetA Danish Nationwide Clinical Trial on Targeted Anti-Cancer Treatment based on Genomic Profiling |
|
|
| Not yet recruiting | 2 | 300 | Europe | Zejula, Capsule, hard, Concentrate and solvent for solution for infusion, Tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Alcensa, Tecentriq, Cotellic, Zelboraf, Herceptin, Perjeta, Kadcyla, Erivedge, Bavencio, Inlyta, Zejula, pemazyre, Retsevmo | Rigshospitalet, Roche, Pfizer | Eligible patients will have an advanced malignant disease for which standard treatment options are no longer available or feasible and acceptable performance status and organ function. Patienter med fremskreden og/eller metastatisk solid tumor, som har oplevet progression under standardbehandling, eller som er intolerante over for standardbehandling, Patients with advanced cancer without curative therapeutic options Patienter med fremskreden kræft uden mulighed for kurativ behandling, Diseases [C] - Cancer [C04] | | | | |
LCMC3, NCT02927301: A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium |
|
|
| Completed | 2 | 181 | US | Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, RO5541267, MPDL3280A | Genentech, Inc. | Non-Small Cell Lung Cancer | 05/20 | 09/23 | | |
|
2019-003916-29: - TREASURE- Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease |
|
|
| Not yet recruiting | 2 | 104 | Europe | Concentrate for solution for infusion, Tecentriq® 1.200 mg | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG, Roche | Small cell lung cancer extensive disease, Small cell lung cancer extensive disease, Diseases [C] - Cancer [C04] | | | | |
NCT03179943: Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma |
|
|
| Active, not recruiting | 2 | 21 | US | Atezolizumab, Guadecitabine | Fox Chase Cancer Center, Stand Up To Cancer, Van Andel Research Institute | Urothelial Carcinoma | 07/20 | 07/22 | | |
2019-003449-14: A Study of the Efficacy and Safety of RO7198457 in Combination with Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Patients Who are CtDNA Positive after Surgical Resection of Stage II-III Non-Small Cell Lung Cancer. |
|
|
| Not yet recruiting | 2 | 80 | Europe | individualized neoantigen-specific therapy (iNeST), RO7198457, Concentrate for solution for infusion, Tecentriq | Genentech Inc., Genentech Inc. c/o F. Hoffmann-La Roche Ltd | Non-small cell lung cancer (NSCLC), NSCLC is the most common type of lung cancer that originally arises from the lungs and could spread to areas near the lungs or distantly to other organs., Diseases [C] - Cancer [C04] | | | | |
2019-002400-40: Prospective study in patients with cancer of the colon or rectum with liver metastasis, of the efficacy and toxicity of standard therapy (chemotherapy + targeted therapy) combined with immunotherapy and internal radiotherapy targeting the liver Etude prospective chez des patients atteints d'un cancer du colon ou du rectum avec des métastase au foie, de l'efficacité et de la toxicité d'une thérapie standard (chimiothérapie + thérapie ciblée) associée à une immunothérapie et une radiothérapie interne ciblant le foie |
|
|
| Not yet recruiting | 2 | 52 | Europe | atezolizumab, RO5541267, Solution for infusion, Concentrate for solution for infusion, CAPÉCITABINE MYLAN, OXALIPLATINE HOSPIRA, Avastin, Tecentriq | Fédération Francophone de Cancérologie Digestive, ROCHE, Boston Scientific | MICROSATELLITE STABLE (MSS) COLORECTAL CANCER WITH LIVER-DOMINANT METASTASIS, METASTATIC COLORECTAL CANCER WITH SPECIFIC MOLECULAR PROFIL (MSS) AND LIVER-DOMINANT METASTASIS, Diseases [C] - Cancer [C04] | | | | |
ETCTN10139, NCT03201458: Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer |
|
|
| Completed | 2 | 86 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI | National Cancer Institute (NCI) | Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Cholangiocarcinoma | 08/20 | 02/24 | | |
| Active, not recruiting | 2 | 138 | Europe | Anti-PD-L1 antibody atezolizumab, SABR, Stereotactic ablative radiotherapy | Gustave Roussy, Cancer Campus, Grand Paris | Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma ) | 05/22 | 10/24 | | |
2020-000569-18: NEOADUVANT ATEZOLIZUMAB AND ADJUVANT ATEZOLIZUMAB + BEVACIZUMAB IN COMBINATION WITH PERCUTANEOUS RADIOFREQUENCY ABLATION OF SMALL HCC ATEZOLIZUMAB NEOADJUVANT ET ATEZOLIZUMAB + BEVACIZUMAB EN ADJUVANT APRES ABLATION PERCUTANEE PAR RADIOFREQUENCE DE CHC DE PETITE TAILLE |
|
|
| Ongoing | 2 | 202 | Europe | Bevacizumab, atezolizumab, L01XC07, RO5541267, Concentrate for solution for infusion, Avastin, Tecentriq | University Hospital of Montpellier, ROCHE | Digestive oncology, Diagnostic of HCC based on histology, Diseases [C] - Digestive System Diseases [C06] | | | | |
2020-000388-21: Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small Cell Lung Cancer (NSCLC) to neoadjuvant ATEZOLIZUMAB plus Carboplatin/Nab Paclitaxe Explorative Studie zur Untersuchung von Immunsignaturen als prädiktiver Marker für ein Therapieansprechen auf eine neoadjuvante Therapie mit ATEZOLIZUMAB, Carboplatin und Nab-Paclitaxel bei an nicht plattenepithelial differenziertem nicht-kleinzelligem Lungenkarzinom im operablen Stadium II, IIIA und ausgewähltem Stadium IIIB (nur T3N2) erkrankten Patienten |
|
|
| Ongoing | 2 | 20 | Europe | Concentrate and solvent for solution for infusion, Powder and solvent for solution for infusion, Tecentriq, Abraxane, CARBOplatin Kabi | Ruprecht-Karls University Heidelberg, Medical Faculty, repr. by HD University Hospital and its Commercial Managing Dir., Roche Pharma AG | resectable Stage II, IIIA and select IIIB non-squamous Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04] | | | | |
2019-000850-78: Atezolizumab combined with BDB001 and immunogenic radiotherapy in participants with advanced solid tumors. Association de l’atezolizumab, du BDB001 et de la radiothérapie immunogénique chez les patients porteurs de tumeurs solides avancées |
|
|
| Not yet recruiting | 2 | 247 | Europe | ATEZOLIZUMAB, BDB001, RO5541267, Concentrate for solution for infusion, TECENTRIQ | Institut Bergonié, INCa | - pancreatic cancer - virus-associated tumors - non-small cell lung cancer - soft-tissue sarcoma - bladder cancer - Triple negative breast cancer - cancer du pancréas - tumeurs viro-induites - cancer bronchique non à petites cellules - sarcomes des tissus mous - cancer de la vessie - cancer du sein triple négatif, - pancreatic cancer - virus-associated tumors - non-small cell lung cancer - soft-tissue sarcoma - bladder cancer - Triple negative breast cancer - cancer du pancréas - tumeurs viro-induites - cancer bronchique non à petites cellules - sarcomes des tissus mous - cancer de la vessie - cancer du sein triple négatif, Diseases [C] - Cancer [C04] | | | | |
2020-000297-17: IMMUNOGAST: An umbrella phase 2 trial to assess personalized targeted IMMUNOtherapy-based regimens in recurrent advanced/metastatic GASTric adenocarcinoma patients IMMUNOGAST: essai « parapluie » de phase 2 évaluant l’efficacité de combinaisons d’immunothérapies personnalisées chez des patients atteints d’adénocarcinomes de l’estomac métastatiques ou avancés en rechute |
|
|
| Not yet recruiting | 2 | 60 | Europe | Bevacizumab, ipatasertib 100mg, atezolizumab, ipatasertib 200mg, L01XC07, RO5532961, RO5541267, Concentrate and solvent for solution for infusion, Film-coated tablet, Concentrate for solution for infusion, Avastin, Tecentriq | Hospices Civils de Lyon, Roche, Inca | For patients with advanced/metastatic gastric adenocarcinomas in progression Pour les patients atteints d’adénocarcinomes de l’estomac métastatiques ou avancés en progression, For patients with advanced/metastatic gastric adenocarcinomas in progression Pour les patients atteints d’adénocarcinomes de l’estomac métastatiques ou avancés en progression, Diseases [C] - Cancer [C04] | | | | |
2020-003759-14: A Study of Atezolizumab with or Without Bevacizumab in Combination with Cisplatin Plus Gemcitabine in Patients with Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 150 | Europe | Atezolizumab, Bevacizumab, RO5541267/F03, RO4876646/F02, Concentrate for solution for infusion, Tecentriq, Avastin | F. Hoffman-La Roche Ltd., F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd., F.Hoffmann-La Roche Ltd. | Biliary tract cancer, Biliary tract cancer is a rare type of cancer that occurs in a bile duct. Patients with advanced biliary tract cancer generally have a poor prognosis., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 146 | Europe | Atezolizumab, Tecentriq, Ipatasertib, Paclitaxel, Doxorubicin, Cyclophosphamide | Queen Mary University of London, Westdeutsche Studiengruppe GmbH (WSG), MedSIR, Hoffmann-La Roche | Triple Negative Breast Cancer | 01/21 | 01/26 | | |
2020-004414-35: Improving public cancer care by implementing precision medicine in Norway |
|
|
| Not yet recruiting | 2 | 2000 | Europe | Alpelisib, Fulvestrant, imatinib, Hydroxyurea, bortezomib, capmatinib, Dactinomycin, tepotinib, dostarlimab, Capsule, hard, Injection, Infusion, Tablet, Capsule, Solution for injection, Powder and solvent for suspension for injection, Powder for solution for injection, Concentrate for solution for infusion, Alecensa, Erivedge, Phesgo, Rozlytrek, Tecentriq, Avastin, Zelboraf, Cotellic, Mekinist, Tafinlar, Alkeran, Piqray, Lynparza, Pemazyre, Tabrecta, Retsevmo, Tepmetko, Gavreto, Zejula | Oslo University Hospital, Oslo University Hospital | Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible., Patients with a biomarker indicating response to the study drug can be included in the trial. Patients with disease characteristics covered in present indications for the study drug are not eligible., Diseases [C] - Cancer [C04] | | | | |
PARCT, NCT03357224: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) |
|
|
| Terminated | 2 | 26 | Europe | Atezolizumab, Tecentriq | European Organisation for Research and Treatment of Cancer - EORTC, Hoffmann-La Roche | Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome | 03/21 | 08/22 | | |
1741-GITCG, NCT03760289: DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer |
|
|
| Not yet recruiting | 2 | 123 | NA | DKN-01, Paclitaxel, Atezolizumab, Tecentric | European Organisation for Research and Treatment of Cancer - EORTC, Hoffmann-La Roche, Leap Therapeutics, Inc. | Esophagogastric Cancer, Biliary Tract Cancer, GastroEsophageal Cancer, Hepatobiliary Neoplasm | 04/21 | 04/22 | | |
2020-005562-34: Integrative analysis of the tumor microenvironment and optimization of the immunotherapy duration in non-small cell lung cancer patients. Analyse intégrée du microenvironnement tumoral et optimisation de la durée du traitement par immunothérapie chez les patients atteints de cancer bronchique non à petites cellules. |
|
|
| Not yet recruiting | 2 | 80 | Europe | PEMBROLIZUMAB, PEMETREXED, CISPLATINE, CARBOPLATINE, PACLITAXEL, ATEZOLIZUMAB, NIVOLUMAB, Solution for infusion, Powder for solution for infusion, KEYTRUDA, ALIMTA, CISPLATINE, CARBOPLATINE, PACLITAXEL, TECENTRIQ, OPDIVO | Institut Bergonié | non-small cell lung cancer cancer du poumon non à petites cellules, advanced non-small cell lung cancer cancer du poumon non à petites cellules avancés, Diseases [C] - Cancer [C04] | | | | |
2018-000254-21: PIONEER is a clinical study in patients with squamous cell carcinoma of the head and neck that is amenable to surgical resection with curative intent. This study will determine the feasibility of preoperative immunotherapy with atezolizumab (Tecentriq®) with or without tocilizumab (Actemra®) |
|
|
| Not yet recruiting | 2 | 40 | Europe | Atezolizumab, tocilizumab, Concentrate for solution for infusion, Tecentriq, Actemra | University Hospital Essen, Hoffmann-La Roche Ltd | local squamous cell carcinoma of the head and neck, local squamous cell carcinoma of the head and neck, Diseases [C] - Cancer [C04] | | | | |
NCT02659384 / 2015-004601-17: Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer |
|
|
| Completed | 2 | 122 | Europe | Bevacizumab, Avastin, atezolizumab, acetylsalicylic acid, placebo | European Organisation for Research and Treatment of Cancer - EORTC | Ovarian Neoplasms | 06/21 | 03/22 | | |
| Completed | 2 | 218 | Europe | Bevacizumab, Irinotecan, Oxaliplatin, L-Leucovorin, 5-fluorouracil, Atezolizumab | Gruppo Oncologico del Nord-Ovest, Roche Pharma AG | Metastatic Colorectal Cancer | 06/21 | 08/23 | | |
2020-002683-31: A Phase II, single-arm trial of addition of Atezolizumab to standard chemotherapy of Platinum and Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung |
|
|
| Not yet recruiting | 2 | 67 | Europe | Concentrate for solution for infusion, Tecentriq® | Technische Universität Dresden, ROCHE Pharma AG | locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung (LCNEC) not eligible for curative treatment lokal fortgeschrittenes oder metastasiertes großzellig-neuroendokrines Lungenkarzinom (LCNEC), nicht für eine kurative Behandlung geeignet, locally advanced or metastatic large-cell neuroendocrine carcinoma of the lung not eligible for curative treatment, Diseases [C] - Cancer [C04] | | | | |
2019-003192-18: Phase II clinical trial with early efficacy testing and adaptive extension for rare malignant tumors |
|
|
| Not yet recruiting | 2 | 175 | Europe | Alectinib, Tecentriq, Vemurafenib, Cobimetinib, Ipatasertib, Herceptin, Perjeta, Inavolisib, 7113755, Capsule, hard, Infusion, Film-coated tablet, Powder for infusion, Concentrate for solution for infusion, Tecentriq, Herceptin, Perjeta | German Cancer Research Center, German Cancer Research Center, Roche Pharma AG | Metastatic or locally advanced malignancies, Previously Treated Advanced tumours, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 21 | US | Ramucirumab, Cyramza, Atezolizumab, Tecentriq, Peripheral blood draw, Biopsy | Washington University School of Medicine, Eli Lilly and Company | Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC | 07/21 | 04/24 | | |
Tricotel, NCT03625141 / 2018-000759-41: A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases |
|
|
| Completed | 2 | 80 | Europe, RoW | Cobimetinib, Cotellic, Atezolizumab, Tecentriq, Vemurafenib, Zelboraf | Hoffmann-La Roche | Metastatic Melanoma | 06/21 | 04/23 | | |
2018-004457-24: PREDIX II HER2 - improving preoperative treatment of HER2 amplified breast cancer |
|
|
| Not yet recruiting | 2 | 190 | Europe | Herceptin, Tecentriq, Kadcyla, Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide, Pertuzumab, Paklitaxel, Solution for injection, Solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Herceptin, Tecentriq, Kadcyla | Karolinska University Hospital, Karolinska University Hospital | Primary breast cancer, Newly diagnosed HER2 amplified breast cancer, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 48 | Europe | Atezolizumab, Doxorubicin | Universitaire Ziekenhuizen Leuven, Roche Pharma AG | Cervical Cancer | 09/21 | 09/22 | | |
| Not yet recruiting | 2 | 33 | Europe | Keytruda, Libtayo - Cemiplimab, Injection/infusion, Pembrolizumab (KEytruda), Atezolizumab (Tecentriq), Nivolumab (Opdivio), Libtayo (Cemiplimab) | Oslo University Hospital, Oslo university Hospital | Non small cell lung cancer, stage IVPatients are eligible if when they are planned to start immunotherapy according to standard routines and are not in need of radiotherapy, Non small cell lung cancer with extensive disease (metastases) and when immunotherapy is planned to start, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-000355-40: Combined therapy with pembrolizumab and lenvatinib in patients with advanced hepatocellular cancer who have had disease progression on previous therapy with atezolizumab and bevacizumab/ IO-based therapy Kombinierte Therapie mit Pembrolizumab und Lenvatinib bei Patienten mit fortgeschrittenem Leberzellkrebs, die unter einer vorherigen Therapie mit Atezolizumab und Bevacizumab / IO ein Fortschreiten ihrer Erkrankung erlitten haben |
|
|
| Not yet recruiting | 2 | 32 | Europe | Pembrolizumab, Lenvatinib, MK-3475, E7080; MK-7902, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, MSD Sharp & Dohme GmbH | advanced stage hepatocellular carcinoma, advanced hepatocellular carcinoma, Diseases [C] - Cancer [C04] | | | | |
| Not yet recruiting | 2 | 178 | RoW | Pabociclib, Endocrine, Talazoparib, Atezolizumab, Pabociclib, Endocrine, Talazoparib, | Samsung Medical Center | Premenopausal HR+/HER2- Metastatic Breast Cancer | 09/21 | 12/27 | | |
ESSENTIAL, NCT05284539: Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer |
|
|
| Recruiting | 2 | 760 | RoW | Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab, Pemetrexed, Bevacizumab, Pembrolizumab, Atezolizumab | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 09/26 | 10/27 | | |
2021-000689-14: Finnish national phase 2 study to evaluate targeted drug treatment in advanced cancer. Yksilöllistä syövänhoitoa selvittävä kansallinen vaiheen 2 lääketutkimus edenneessä syövässä. |
|
|
| Not yet recruiting | 2 | 250 | Europe | abemaciclib, pralsetinib, Tablet, Capsule, hard, Injection, Infusion, Capsule, Stivarga, Alecensa, Cotellic, Erivedge, Phesgo, Rozlytrek, Tecentriq, Zelboraf, Verzenios, Retsevmo, Erleada, Tafinlar, Mekinist, Gavreto, Lynparza | Helsinki University Hospital, Helsinki University Hospital | Patients with an advanced solid tumor for which standard treatment options no longer exist and with acceptable performance status and organ function with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test., Patients with advanced cancer where standard treatment options no longer exist. Potilaat, jotka sairastava edennyttä syöpää, johon tavanomaiset hoitolinjat eivät enää tehoa., Diseases [C] - Cancer [C04] | | | | |
GFPC 06-2018, NCT04042558 / 2019-000727-41: A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies |
|
|
| Recruiting | 2 | 149 | Europe | Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab | Centre Francois Baclesse, GFPC | NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive, ROS1 Gene Mutation | 10/21 | 06/24 | | |
2020-002715-21: Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy– a Phase II study |
|
|
| Not yet recruiting | 2 | 80 | Europe | Atezolizumab, IMM-101, L01XC32, Concentrate for solution for infusion, Suspension for injection, Tecentriq (R) | AIO-Studien-gGmbH, F. Hoffmann-La Roche Ltd, Immodulon Therapeutics Ltd. | Patients with MSI-high or MMR-deficient stage III colorectal cancer who are ineligible for or who refuse oxaliplatin-based chemotherapy after R0 tumor resection (main study) or planned resection (sub-study), patients with stage III colon or rectum cancer who are ineligible or refuse oxaliplatin-based chemotherape after surgical removal of the tumor (main study) oder the surgery is planned (sub-study), Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 172 | Europe, Canada, US, RoW | Tiragolumab, RO7092284, Atezolizumab, RO5541267, Tecentriq | Hoffmann-La Roche | Cervical Cancer | 12/21 | 12/24 | | |
|
2020-004938-38: ADVANCE: A clinical study of Atezolizumab and Derazantinib for patients with advanced intrahepatic cholangiocarcinoma with gene FGFR2 fusions/rearrangements Die ADVANCE Studie: Eine einarmige, offene klinische Studie der Phase II zur Behandlung mit Atezolizumab und Derazantinib bei Patienten mit einem fortge-schrittenen intrahepatischen Cholangiokarzinom, das molekulare FGFR2 Alterationen (Gen-Fusionen/Rearrangements) aufweist |
|
|
| Not yet recruiting | 2 | 37 | Europe | Derazantinib, Derazantinib•2HCl / BAL087 / BAL0000087-001, Concentrate for solution for infusion, Capsule, hard, Tecentriq® 1.200 mg | Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, ROCHE Pharma AG, Basilea Pharmaceutica International Ltd. | Advanced non-resectable intrahepatic cholangiocarcinoma with positively confirmed FGFR2 fusion/rearrangements via NGS-Analysis, Advanced and inoperable intrahepatic bile duct cancer with positively confirmed FGFR2 genetic alterations, Diseases [C] - Cancer [C04] | | | | |
NCT03713944: Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer |
|
|
| Terminated | 2 | 30 | US | Carboplatin, Pemetrexed, Atezolizumab, Bevacizumab | Nasser Hanna, Genentech, Inc. | NSCLC Stage IV, NSCLC, Recurrent | 12/21 | 12/21 | | |
CLIMB, NCT03698461: Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab |
|
|
| Completed | 2 | 20 | RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin, Oxaliplatin, Levoleucovorin, 5-FU, 5-fluorouracil | Asan Medical Center, Hoffmann-La Roche | Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms, Rectal Neoplasms | 12/21 | 10/23 | | |
2021-002695-40: A Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have already received chemotherapy and radiotherapy. Estudio de Atezolizumab En Pacientes Con Cáncer De Pulmón No Microcítico En Estadio III Localmente Avanzado E Irresecable Que No Han Progresado Después De La Quimioterapia y radioterapia |
|
|
| Not yet recruiting | 2 | 120 | Europe | Concentrate for solution for infusion, TECNETRIQ® | Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffmann La-Roche Ltd, F.Hoffmann-La Roche Ltd | Non-Small Cell Lung Cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM), NSCLC is a disease in which malignant (cancer) cells form in the tissues of the lung. Smoking is the major risk factor for NSCLC. El CPNM es una enfermedad en la que se forman células malignas (cancerosas) en los tejidos del pulmón. El tabaquismo es el principal factor de riesgo del CPNM., Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 2 | 20 | Europe | Atezolizumab, MPDL3280A, Capecitabine, L01BC06, Oxaliplatin, L01XA03, Docetaxel, L01CD02 | The Netherlands Cancer Institute, Hoffmann-La Roche | Stomach Cancer, Gastro Esophageal Junction Cancer | 01/22 | 01/22 | | |
ML41256, NCT04426825: A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 23 | RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin | Hoffmann-La Roche | Carcinoma, Non-Small-Cell Lung | 01/22 | 02/23 | | |
CHEERS, NCT03511391: CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors |
|
|
| Completed | 2 | 99 | Europe | Nivolumab or Pembrolizumab or Atezolizumab, Immune checkpoint inhibitor, SBRT, Stereotactic body radiotherapy, SABR, Stereotactic ablative radiotherapy | University Hospital, Ghent, GZA Ziekenhuizen Campus Sint-Augustinus, AZ Sint-Lucas Brugge, Jules Bordet Institute, AZ Sint-Lucas Gent | Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Head and Neck Cancer | 02/22 | 01/24 | | |
NCT03737123: Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma |
|
|
| Terminated | 2 | 6 | US | Carboplatin, paraplatin, Gemcitabine, Gemzar, Atezolizumab, Tecentriq, Docetaxel, Taxotere | Nabil Adra, Genentech, Inc., Indiana University School of Medicine | Urothelial Carcinoma | 03/22 | 05/22 | | |
2019-000914-12: Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors |
|
|
| Not yet recruiting | 2 | 27 | Europe | TECENTRIQ (atezolizumab), GAZYVA (Obinutuzumab/, Infusion, Injection, TECENTRIQ (atezolizumab), GAZYVA (Obinutuzumab) | University of Cologne, F. Hoffmann La Roche | • Melanoma: unresectable stage III with macroscopic lymph node, in transit/satellite metastasis or stage IV after ≥ 2 lines of therapy (incl. checkpoint blockade, BRAF inhibitor)• Prostate carcinoma: castration-resistant, 2 lines of chemotherapy failed• CTCL: ≥ stage IIB, ≥ 2 previous lines of treatment, Patients with late stage Melanoma, Prostate carcinoma or Cutaneous T cell lymphoma (CTCL), Diseases [C] - Cancer [C04] | | | | |
2020-002853-11: A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, with or Without Platinum-Based Chemotherapy, in Patients with Previously Untreated Locally Advanced Resectable Stage II, IIIa, or Select IIIb Non-Small Cell Lung Cancer. |
|
|
| Not yet recruiting | 2 | 82 | Europe | tiragolumab, RO7092284/F03-01, Concentrate for solution for infusion, Tecentriq | F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd | Non-Small Cell Lung Cancer., Lung cancer that has spread to areas near the lungs or other organs and has not yet been treated by chemotherapy., Diseases [C] - Cancer [C04] | | | | |
| Not yet recruiting | 2 | 206 | Europe | Atezolizumab, Bevacizumab | Fondazione Ricerca Traslazionale | Non-small-cell Lung Cancer Patients | 05/22 | 04/23 | | |
2019-001197-28: Can 89Zr-atezolizumab PET scan identify patients with metastatic invasive lobular breast cancer who will respond to chemotherapy-immune checkpoint inhibition? |
|
|
| Not yet recruiting | 2 | 10 | Europe | [89Zr]-Atezolizumab, [89Zr]-Atezolizumab, Solution for injection | University Medical Center Groningen, UMCG Kanker Research Fonds | Lobular metastatic breast cancer, Lobular metastatic breast cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | | | | |
NCT05110781: Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site |
|
|
| Terminated | 2 | 1 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Therapeutic Conventional Surgery | Arnaud Bewley, MD, National Cancer Institute (NCI), Genentech, Inc. | Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | 05/22 | 04/23 | | |
| Completed | 2 | 162 | Europe, US, RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo, Cisplatin, Gemcitabine | Hoffmann-La Roche, F. Hoffmann-La Roche Ltd., F.Hoffmann-La Roche Ltd. | Biliary Tract Cancer | 05/22 | 08/23 | | |
|
2022-000234-42: Stool transplantation combined with atezolizumab plus bevacizumab in patients with liver cancer who failed to respond to prior immunotherapy – the FAB-HCC Trial Stuhltransplantation in Kombination mit Atezolizumab plus Bevacizumab bei Patienten mit Leberkrebs, die nicht auf Immuntherapie angesprochen haben - die FAB-HCC-Studie |
|
|
| Not yet recruiting | 2 | 12 | Europe | Atezolizumab, Bevacizumab, RO5541267, RO4876646, Concentrate for solution for infusion, Tecentriq 1200mg, Avastin | Medical University of Vienna, Div. of Gastroenterology & Hepatology, F. Hoffmann-La Roche Ltd | Hepatocellular carcinoma, Liver cancer, Diseases [C] - Cancer [C04] | | | | |
Match, NCT04622228: Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 56 | RoW | Atezolizumab, Tecentriq, Cisplatin, Carboplatin, Etoposide, Thoracic radiation therapy (TRT) | Hoffmann-La Roche | Carcinoma, Small Cell Lung | 06/22 | 06/24 | | |
NCT03544723: Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. |
|
|
| Recruiting | 2 | 40 | US | Ad-p53, anti-PD-1/anti-PD-L1, nivolumab, pembrolizumab, atezolizumab, durvalumab | MultiVir, Inc. | Solid Tumor, Lymphoma | 06/22 | 12/22 | | |
ChiCTR2100049831: Efficacy and safety of radiotherapy combined with Atezolizumab plus Bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus: an open-label, single-arm, exploratory trial |
|
|
| Recruiting | 2 | 42 | China | Radiotherapy combined with Atezolizumab plus Bevacizumab | The Third Affiliated Hospital of the Second Military Medical University of the Chinese people's Liberation Army ; The Third Affiliated Hospital of the Second Military Medical University of the Chinese people's Liberation Army, Self-raised | hepatocellular carcinoma complicated with portal vein tumor thrombus | | | | |
ChiCTR2100049830: Efficacy and safety of GEMOX chemotherapy combined with Atezolizumab plus Bevacizumab for advanced biliary tract cancer: an open-label, single-arm, exploratory trial |
|
|
| Recruiting | 2 | 46 | | atilizumab and bevacizumab combined with GEMOX chemotherapy | The Third Affiliated Hospital of the Second Military Medical University of the Chinese people's Liberation Army; The Third Affiliated Hospital of the Second Military Medical University of the Chinese people's Liberation Army, Self-raised | Advanced biliary tract cancer | | | | |
ChiCTR2100049829: Efficacy and safety of TACE combined with atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma (BCLC stage-B): an open-label, single-arm, exploratory trial |
|
|
| Recruiting | 2 | 49 | | atilizumab and bevacizumab combined with TACE | The Third Affiliated Hospital of the Second Military Medical University of the Chinese people's Liberation Army; The Third Affiliated Hospital of the Second Military Medical University of the Chinese people's Liberation Army, Self-raised | unresectable hepatocellular carcinoma (BCLC stage B) | | | | |
NCT04423185: PLATFORM Study of Precision Medicine for Rare Tumors |
|
|
| Not yet recruiting | 2 | 770 | NA | Almonertinib 110 MG, HS-10296, AMEILE, Dacomitinib 45 MG, Vizimpro, Alectinib 150 MG, Alecensa, Crizotinib 250 MG, Xalkori, Pyrotinib 160/80 MG, SHR-1258, Imatinib 400 MG, Gleevec, Niraparib 200/300 MG, Niraparix, Palbociclib 125mg, Ibrance, Vemurafenib 240 MG, Zelboraf, Sintilimab 100MG, Tyvyt, Atezolizumab 1680 MG, TECENTRIQ | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Rare Tumor | 07/22 | 07/23 | | |
NCT04696939: Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients |
|
|
| Not yet recruiting | 2 | 100 | RoW | Atezolizumab, Carboplatin, Etoposide | Shanghai Pulmonary Hospital, Shanghai, China | Small-cell Lung Cancer, Neoadjuvant Therapy | 08/22 | 10/23 | | |
NCT04373369: Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 11 | US | Vorolanib, X-82, Atezolizumab, Tecentriq | Washington University School of Medicine, Xcovery Holdings, Inc. | Extensive-stage Small Cell Lung Cancer | 08/22 | 07/25 | | |
ML41186, NCT04091217: Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma |
|
|
| Completed | 2 | 43 | RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin | Hoffmann-La Roche | Melanoma | 08/22 | 09/23 | | |
NCT04690686: Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). |
|
|
| Recruiting | 2 | 24 | RoW | LW-02 device immunopheresis combined with atezolizumab, Plasma soluble TNF receptor pulldown + immunotherapy., LW-02 device immunopheresis combined with weekly paclitaxel, Plasma soluble TNF receptor pulldown + chemotherapy, LW-02 device immunopheresis, Plasma soluble TNF receptor pulldown | Immunicom Inc | Non Small Cell Lung Cancer | 08/22 | 12/22 | | |
| Completed | 2 | 32 | Europe | Arm A: Atezolizumab and Radiotherapy, Arm B: Atezolizumab | The Netherlands Cancer Institute, Hoffmann-La Roche | Penile Cancer | 09/22 | 09/23 | | |
|
| Active, not recruiting | 2 | 12 | Europe | Atezolizumab, Tecentriq | Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Istituto Cantonale di Patologia, Clinical Trial Unit Ente Ospedaliero Cantonale | NSCLC Stage IV | 01/23 | 12/24 | | |
NCT04610684: Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases |
|
|
| Terminated | 2 | 3 | US | Carboplatin, paraplatin, Etoposide, VP-16, Atezolizumab, Imfinzi | Jeffrey Clarke, Genentech, Inc., Duke University | Small-cell Lung Cancer, Brain Metastases | 07/22 | 09/22 | | |
NCT04099836: Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib |
|
|
| Terminated | 2 | 7 | US | Atezolizumab, TECENTRI, Bevacizumab, Avastin | Duke University | Non Small Cell Lung Cancer | 11/22 | 06/23 | | |
2019-002364-27: A study to assess atezolizumab in combination with dual HER2 blockade plus epirubicin as neoadjuvant therapy for HER2-positive early breast cancer |
|
|
| Not yet recruiting | 2 | 58 | Europe | Atezolizumab, Pertuzumab, Herceptin, RO5541267/F03, RO4368451, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Tecentriq, Perjeta, Herceptin | ABCSG (Austrian Breast & Colorectal Cancer Study Group), Roche Austria GmbH | HER2-positive early breast cancer, Early diagnosed with breast cancer that is HER2-positive, Diseases [C] - Cancer [C04] | | | | |
2021-005887-24: Tiraglolumab Atezolizumab and chemoradiotherapy in Localized Anal carcinoma (TIRANUS) Tiraglolumab Atezolizumab y quimio-radioterapia en carcinma localizado del Ano (TIRANUS) |
|
|
| Ongoing | 2 | 45 | Europe | Tiragolumab, Atezolizumab, Concentrate for solution for infusion, TECENTRIQ | Grupo Español Multidisciplinar de Cáncer Digestivo (GEMCAD), ROCHE Ltd | Locallized squamous cell carcinoma of the anal canal in the first-line setting. Carcinoma epidermoide localizado del canal anal en primera línea., Carcinoma of the anal canal Carcinoma del canal anal, Diseases [C] - Cancer [C04] | | | | |
NCT04458922: Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma |
|
|
| Active, not recruiting | 2 | 27 | Canada, US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography | National Cancer Institute (NCI) | Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma | 11/22 | 12/24 | | |
NCT03206203: Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer |
|
|
| Active, not recruiting | 2 | 106 | US | Atezolizumab, Carboplatin, Laboratory Biomarker, Quality-of-Life Assessment | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Genentech, Inc. | Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative, Invasive Breast Cancer | 11/22 | 11/24 | | |
| Recruiting | 2 | 154 | Europe | Atezolizumab, Tecentriq, Everolimus, Afinitor, Cobimetinib, Cotellic | Uppsala University Hospital | Solid Tumor | 01/24 | 10/24 | | |
HCRN BRE19-433, NCT04690855: A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer |
|
|
| Terminated | 2 | 1 | US | Talazoparib, Talzenna, Atezolizumab, Tecentriq, Radiation | Mylin A. Torres, MD, Genentech, Inc., Pfizer, Emory University | Breast Cancer, Triple Negative Breast Cancer | 02/22 | 12/22 | | |
NCT05007613: Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 37 | RoW | Cabozantinib 40 MG, Cabometyx, Atezolizumab Injection, Tecentriq | National Taiwan University Hospital, Ipsen, Roche Pharma AG | Esophageal Cancer, Metastatic Cancer, Squamous Cell Carcinoma | 12/22 | 06/23 | | |
